TQF3250 / Sino Biopharm - LARVOL DELTA

A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Genetic Disorders • Obesity

TQF3250-Ib-01: A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Diabetes

…Sino Biopharmaceutical…announces that the clinical trial application for its self-developed innovative drug, TQF3250 capsules…has been approved by the China National Medical Products Administration (NMPA) and the United States Food and Drug Administration (FDA), intended for weight loss (HKEXnews)

IND • New trial • Obesity